A Phase 3 interventional study of eltrombopag and Placebo in Purpura, Thrombocytopaenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 115 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-18.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 3rd largest by enrollment, is one of 2 that started in 2006, is one of 9 in phase 3, and was the 3rd registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18–75
Renata PLC · Sites in Bangladesh
Ages 18–70
Nahda University · Sites in Egypt
Ages 18–65
Novartis Pharmaceuticals
Ages 5–17
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 197 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 36 interventional studies. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
11 studies in Purpura, Thrombocytopenic, Idiopathic by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 11 finished, 6 (55%) have results posted.
Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by GlaxoSmithKline, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2006, is one of 4 in phase 3, and was the 2nd registered.
GlaxoSmithKline’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2005.
1 of the studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189910Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 11 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The rationale for this Phase III study is to evaluate the 6 month safety and efficacy of eltrombopag in the treatment of previously treated subjects with chronic ITP. The starting dose of eltrombopag, 50 mg, once daily was selected based upon the observed efficacy, safety and pharmacokinetics in a dose-finding Study (TRA100773). This Phase III study is a randomized, double-blind, placebo-controlled, Phase III study, to evaluate efficacy, safety and tolerability of eltrombopag, initially administered as 50 mg oral tablets once daily for six months in adult subjects with previously treated chronic ITP. Subjects will be randomized 2:1, eltrombopag to placebo, and will be stratified based upon splenectomy status, use of ITP medication at baseline and baseline platelet count less than or equal to 15,000/µL. Subjects will receive study medication for 6 months, during which the dose of study medication may be adjusted based upon individual platelet counts. In addition, subjects may taper off concomitant ITP medications and may receive any rescue treatments as dictated by local standard of care. After discontinuation of study medication, subjects will complete follow-up visits at weeks 1, 2, 4 and months 3 and 6.
A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult subjects with previously treated chronic idiopathic thrombocytopenic purpura (ITP).
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
This study's enrollment of 197 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Browse Purpura, Thrombocytopenic, Idiopathic studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Purpura. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
Drug: eltrombopag
Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
Drug: Placebo
Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down
Percentage of Responders
The percentage of evaluable participants who achieved a platelet response (defined as a platelet count between 50,000 and 400,000 microliter) at each nominal on-therapy day and 4 weeks post-treatment
Time frame: Baseline; each on-therapy treatment day; Weeks 10, 14, 18, 22, and 26; and Weeks 1, 2, and 4 post-treatment
Summary of Median Platelet Counts
Platelet counts were measured by blood draw.
Time frame: Baseline; Day 8 through Week 26 on-treatment; and 1, 2, 4 week follow-up visits
Percentage of Participants Initiating Rescue Treatment On-therapy
Percentage of participants initiating new ITP medication, an increased dose of concomitant ITP medication from baseline, platelet transfusion, or splenectomy.
Time frame: Anytime from Day 1 to Week 26
Maximum and Total Weeks of Platelet Response
Response is defined as a platelet count between 50,000 and 400,000 platelets per microliter.
Time frame: Day 1 through Week 26 on-treatment
Percentage of Participants With a Reduction in Use of Baseline ITP Medication
Percentage of participants who experienced a reduction in their baseline concomitant ITP medication use
Time frame: From Day 1 through Week 26 on-treatment
WHO Bleeding Scale
Summary of World Health Organization (WHO) bleeding scores at each nominal visit. WHO Grades 1-4 = any bleeding; WHO Grades 2-4 = clinically significant bleeding
Time frame: Baseline, all nominal visits on-therapy defined as Day 8, Day 15, Day 22, Day 29, Day 36, Day 43, Week 10, Week 14, Week 18, Week 22, Week 26, and 1, 2 and 4 week follow-up visits
HR-QoL Instrument and Domain Scores From the SF-36v2 Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment
Health-related quality of life (HR-QoL) patient reported outcomes from the short form-36v2 (SF-36v2) questionnaire. Scores could range from 0 (worst possible) to 100 (best possible).
Time frame: Baseline, Week 6, Week 14, and Week 26/Early Withdrawal
HR-QoL Instrument and Domain Scores From the FACIT-F Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment
Health-related quality of life (HR-QoL) patient reported outcomes from the functional assessment of chronic illness therapy fatigue (FACIT-F) questionnaire. Scores could range from 0 (worst possible) to 52 (best possible).
Time frame: Baseline, Week 6, Week 14, and Week 26/Early Withdrawal
HR-QoL Instrument and Domain Scores for the FACT-Th Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment
Health-related quality of life (HR-QoL) patient reported outcomes from the functional assessment of cancer therapy thrombocytopenia (FACT-Th) questionnaire (six selected items). Scores could range from 0 (worst possible) to 24 (best possible).
Time frame: Baseline, Week 6, Week 14, and Week 26/Early Withdrawal
HR-QoL Instrument and Domain Scores From the MEI-SF Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment
Health-related quality of life (HR-QoL) patient reported outcomes from the motivation and energy inventory-short form (MEI-SF) questionnaire. Scores could range from 0 (worst possible) to 72 (best possible).
Time frame: Baseline, Week 6, Week 14, and Week 26/Early Withdrawal
| Milestone | Placebo | Eltrombopag 50 mg QD |
|---|---|---|
| Started | 62 | 135 |
| Completed | 55 | 112 |
| Not completed | 7 | 23 |
| Withdrew: Adverse event | 4 | 13 |
| Withdrew: Withdrawal by subject | 2 | 4 |
| Withdrew: Lost to follow-up | 0 | 3 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Non-compliance | 0 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
The percentage of evaluable participants who achieved a platelet response (defined as a platelet count between 50,000 and 400,000 microliter) at each nominal on-therapy day and 4 weeks post-treatment
| Percentage of participants | Placebo | Eltrombopag 50 mg QD |
|---|---|---|
| Baseline | 2 | 1 |
| Day 8 | 7 | 37 |
| Day 15 | 8 | 46 |
| Day 22 | 8 | 51 |
| Day 29 | 10 | 49 |
| Day 36 | 8 | 56 |
| Day 43 | 14 | 54 |
| Week 10 | 17 | 52 |
| Week 14 | 18 | 46 |
| Week 18 | 17 | 46 |
| Week 22 | 19 | 49 |
| Week 26 | 17 | 52 |
| 1 Week Follow-up | 15 | 42 |
| 2 Week Follow-up | 18 | 22 |
| 4 Week Follow-up | 14 | 20 |
Platelet counts were measured by blood draw.
| platelets/microliter (ul) | Placebo | Eltrombopag 50 mg QD |
|---|---|---|
| Baseline | 16,000 (2000 to 87,000) | 16,000 (0 to 78,000) |
| Day 8 | 17,500 (3000 to 354,000) | 36,000 (1000 to 593,000) |
| Day 15 | 18,000 (2000 to 214,000) | 54,000 (2000 to 750,000) |
| Day 22 | 18,500 (1000 to 271,000) | 54,000 (1000 to 507,000) |
| Day 29 | 18,000 (3000 to 313,000) | 53,000 (1000 to 400,000) |
| Day 36 | 19,000 (4000 to 297,000) | 60,000 (1000 to 952,000) |
| Day 43 | 20,000 (3000 to 275,000) | 59,000 (1000 to 545,000) |
| Week 10 | 20,000 (0 to 293,000) | 61,500 (1000 to 433,000) |
| Week 14 | 17,500 (1000 to 303,000) | 60,000 (1000 to 409,000) |
| Week 18 | 20,500 (2000 to 281,000) | 61,000 (3000 to 363,000) |
| Week 22 | 23,000 (1000 to 315,000) | 72,000 (3000 to 408,000) |
| Week 26 | 23,000 (2000 to 315,000) | 73,500 (1000 to 429,000) |
| 1 Week Follow-up | 19,000 (0 to 323,000) | 38,500 (1000 to 409,000) |
| 2 Week Follow-up | 18,000 (1000 to 340,000) | 21,000 (1000 to 434,000) |
| 4 Week Follow-up | 18,000 (1000 to 301,000) | 24,000 (1000 to 446,000) |
Percentage of participants initiating new ITP medication, an increased dose of concomitant ITP medication from baseline, platelet transfusion, or splenectomy.
| Percentage of participants | Placebo | Eltrombopag 50 mg QD |
|---|---|---|
| Participants who received rescue treatment | 40 | 18 |
| Participants who did not receive rescue treatment | 60 | 82 |
Response is defined as a platelet count between 50,000 and 400,000 platelets per microliter.
| Weeks | Placebo | Eltrombopag 50 mg QD |
|---|---|---|
| Maximum continuous Response | 0 (0 to 25) | 8.1 (0 to 26) |
| Cumulative Response | 0 (0 to 25) | 10.9 (0 to 26) |
Percentage of participants who experienced a reduction in their baseline concomitant ITP medication use
| Percentage of participants | Placebo | Eltrombopag 50 mg QD |
|---|---|---|
| Participants who reduced/discontinued ITP therapy | 32 | 59 |
| Participants not reducing/discont. ITP therapy | 68 | 41 |
Summary of World Health Organization (WHO) bleeding scores at each nominal visit. WHO Grades 1-4 = any bleeding; WHO Grades 2-4 = clinically significant bleeding
| Percentage of participants | Placebo | Eltrombopag 50 mg QD |
|---|---|---|
| Baseline, WHO Grades 1-4 | 77 | 73 |
| Day 8, WHO Grades 1-4 | 73 | 56 |
| Day 15, WHO Grades 1-4 | 68 | 39 |
| Day 22, WHO Grades 1-4 | 67 | 38 |
| Day 29, WHO Grades 1-4 | 56 | 37 |
| Day 36, WHO Grades 1-4 | 66 | 23 |
| Day 43, WHO Grades 1-4 | 59 | 23 |
| Week 10, WHO Grades 1-4 | 49 | 22 |
| Week 14, WHO Grades 1-4 | 57 | 23 |
| Week 18, WHO Grades 1-4 | 59 | 22 |
| Week 22, WHO Grades 1-4 | 46 | 18 |
| Week 26, WHO Grades 1-4 | 56 | 22 |
| 1 Week Follow-up, WHO Grades 1-4 | 59 | 28 |
| 2 Week Follow-up, WHO Grades 1-4 | 56 | 50 |
| 4 Week Follow-up, WHO Grades 1-4 | 59 | 46 |
| Baseline, WHO Grades 2-4 | 28 | 22 |
| Day 8, WHO Grades 2-4 | 20 | 16 |
| Day 15, WHO Grades 2-4 | 22 | 8 |
| Day 22, WHO Grades 2-4 | 21 | 11 |
| Day 29, WHO Grades 2-4 | 19 | 10 |
| Day 36, WHO Grades 2-4 | 19 | 7 |
| Day 43, WHO Grades 2-4 | 19 | 5 |
| Week 10, WHO Grades 2-4 | 13 | 9 |
| Week 14, WHO Grades 2-4 | 17 | 5 |
| Week 18, WHO Grades 2-4 | 18 | 2 |
| Week 22, WHO Grades 2-4 | 10 | 8 |
| Week 26, WHO Grades 2-4 | 15 | 7 |
| 1 Week Follow-up, WHO Grades 2-4 | 20 | 11 |
| 2 Week Follow-up, WHO Grades 2-4 | 18 | 16 |
| 4 Week Follow-up, WHO Grades 2-4 | 21 | 13 |
Health-related quality of life (HR-QoL) patient reported outcomes from the short form-36v2 (SF-36v2) questionnaire. Scores could range from 0 (worst possible) to 100 (best possible).
| Points on a scale (0-100) | Placebo | Eltrombopag 50 mg QD |
|---|---|---|
| SF-36v2 physical function, Baseline | 75.0 ± 21.7 | 73.1 ± 26.8 |
| SF-36v2 physical function, Week 6 | 76.5 ± 20.8 | 78.0 ± 24.4 |
| SF-36v2 physical function, Week 14 | 77.6 ± 20.0 | 78.9 ± 22.5 |
| SF-36v2 physical funct., Week 26/Early Withdrawal | 75.8 ± 22.6 | 80.6 ± 21.7 |
| SF-36v2 physical role, Baseline | 64.5 ± 26.7 | 64.5 ± 30.5 |
| SF-36v2 physical role, Week 6 | 66.9 ± 25.4 | 73.7 ± 27.4 |
| SF-36v2 physical role, Week 14 | 67.2 ± 25.8 | 72.9 ± 24.9 |
| SF-36v2 physical role, Week 26/Early Withdrawal | 67.5 ± 27.1 | 73.7 ± 25.4 |
| SF-36v2 bodily pain, Baseline | 70.0 ± 23.2 | 75.2 ± 27.8 |
| SF-36v2 bodily pain, Week 6 | 69.9 ± 25.9 | 78.5 ± 25.4 |
| SF-36v2 bodily pain, Week 14 | 68.3 ± 24.8 | 77.6 ± 25.8 |
| SF-36v2 bodily pain, Week 26/Early Withdrawal | 68.5 ± 25.0 | 75.7 ± 26.6 |
| SF-36v2 general health, Baseline | 53.7 ± 21.8 | 56.0 ± 21.3 |
| SF-36v2 general health, Week 6 | 55.9 ± 21.4 | 59.7 ± 21.5 |
| SF-36v2 general health, Week 14 | 52.8 ± 23.2 | 59.3 ± 20.7 |
| SF-36v2 general health, Week 26/Early Withdrawal | 53.3 ± 24.9 | 57.3 ± 23.1 |
| SF-36v2 vitality, Baseline | 56.7 ± 20.2 | 55.1 ± 26.3 |
| SF-36v2 vitality, Week 6 | 59.0 ± 20.0 | 62.1 ± 22.7 |
| SF-36v2 vitality, Week 14 | 56.8 ± 22.3 | 61.0 ± 22.4 |
| SF-36v2 vitality, Week 26/Early Withdrawal | 57.5 ± 22.4 | 60.0 ± 23.3 |
| SF-36v2 social function, Baseline | 76.1 ± 21.7 | 72.7 ± 28.3 |
| SF-36v2 social function, Week 6 | 78.0 ± 21.4 | 77.6 ± 26.2 |
| SF-36v2 social function, Week 14 | 73.4 ± 25.8 | 78.4 ± 22.6 |
| SF-36v2 social function, Week 26/Early Withdrawal | 75.0 ± 25.8 | 79.0 ± 24.2 |
| SF-36v2 emotional role, Baseline | 73.4 ± 25.4 | 69.1 ± 30.9 |
| SF-36v2 emotional role, Week 6 | 73.1 ± 24.6 | 77.5 ± 25.9 |
| SF-36v2 emotional role, Week 14 | 73.3 ± 22.9 | 74.1 ± 25.2 |
| SF-36v2 emotional role, Week 26/Early Withdrawal | 71.5 ± 26.5 | 76.9 ± 25.4 |
| SF-36v2 mental health, Baseline | 70.3 ± 18.7 | 68.0 ± 21.0 |
| SF-36v2 mental health, Week 6 | 71.7 ± 18.3 | 71.8 ± 19.0 |
| SF-36v2 mental health, Week 14 | 68.6 ± 20.4 | 70.6 ± 19.3 |
| SF-36v2 mental health, Week 26/Early Withdrawal | 68.6 ± 22.8 | 70.2 ± 21.6 |
| SF-36v physical component summary, Baseline | 45.6 ± 8.3 | 46.9 ± 9.7 |
| SF-36v physical component summary, Week 6 | 46.2 ± 8.3 | 48.7 ± 9.0 |
| SF-36v physical component summary, Week 14 | 46.3 ± 8.3 | 49.0 ± 8.1 |
| SF-36v physical component summary, Week 26/EW | 46.2 ± 8.1 | 48.7 ± 8.6 |
| SF-36v2 mental component summary, Baseline | 46.4 ± 10.1 | 44.3 ± 12.6 |
| SF-36v2 mental component summary, Week 6 | 46.8 ± 10.0 | 47.2 ± 11.1 |
| SF-36v2 mental component summary, Week 14 | 45.3 ± 11.1 | 46.2 ± 11.3 |
| SF-36v2 mental component summary, Week 26/EW | 45.2 ± 12.3 | 46.5 ± 12.4 |
Health-related quality of life (HR-QoL) patient reported outcomes from the functional assessment of chronic illness therapy fatigue (FACIT-F) questionnaire. Scores could range from 0 (worst possible) to 52 (best possible).
| Points on a scale (0-52) | Placebo | Eltrombopag 50 mg QD |
|---|---|---|
| Baseline | 36.3 ± 9.0 | 36.0 ± 12.2 |
| Week 6 | 38.3 ± 8.2 | 39.2 ± 9.7 |
| Week 14 | 36.9 ± 10.2 | 39.5 ± 9.9 |
| Week 26/Early Withdrawal | 37.0 ± 11.3 | 39.2 ± 10.1 |
Health-related quality of life (HR-QoL) patient reported outcomes from the functional assessment of cancer therapy thrombocytopenia (FACT-Th) questionnaire (six selected items). Scores could range from 0 (worst possible) to 24 (best possible).
| Points on a scale (0-24) | Placebo | Eltrombopag 50 mg QD |
|---|---|---|
| Baseline | 14.8 ± 5.8 | 13.5 ± 5.8 |
| Week 6 | 15.1 ± 5.7 | 15.9 ± 6.0 |
| Week 14 | 15.3 ± 5.4 | 16.7 ± 5.6 |
| Week 26/Early Withdrawal | 15.3 ± 6.0 | 16.0 ± 6.1 |
Health-related quality of life (HR-QoL) patient reported outcomes from the motivation and energy inventory-short form (MEI-SF) questionnaire. Scores could range from 0 (worst possible) to 72 (best possible).
| Points on a scale (0-72) | Placebo | Eltrombopag 50 mg QD |
|---|---|---|
| Baseline | 71.3 ± 17.2 | 72.7 ± 21.4 |
| Week 6 | 73.4 ± 16.4 | 76.2 ± 19.5 |
| Week 14 | 71.1 ± 20.5 | 76.9 ± 20.5 |
| Week 26/Early Withdrawal | 72.0 ± 21.7 | 76.7 ± 20.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 11/61 (18%) | 56/61 (91.8%) |
| Eltrombopag 50 mg QD | — | 16/135 (11.9%) | 120/135 (88.9%) |
| Event | Placebo | Eltrombopag 50 mg QD |
|---|---|---|
| CataractEye disorders | 2/61 | 2/135 |
| HeadacheNervous system disorders | 0/61 | 3/135 |
| Cataract subcapsularEye disorders | 1/61 | 0/135 |
| Retinal haemorrhageEye disorders | 1/61 | 0/135 |
| Brain stem haemorrhageNervous system disorders | 1/61 | 0/135 |
| Alanine aminotransferase (ALT) increasedInvestigations | 1/61 | 1/135 |
| Heart rate increasedInvestigations | 1/61 | 0/135 |
| Renal function test abnormalInvestigations | 1/61 | 0/135 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/61 | 0/135 |
| CellulitisInfections and infestations | 1/61 | 0/135 |
| Event | Placebo | Eltrombopag 50 mg QD |
|---|---|---|
| HeadacheNervous system disorders | 20/61 | 40/135 |
| NasopharyngitisInfections and infestations | 12/61 | 14/135 |
| FatigueGeneral disorders | 8/61 | 13/135 |
| DiarrhoeaGastrointestinal disorders | 6/61 | 17/135 |
| NauseaGastrointestinal disorders | 4/61 | 17/135 |
| Upper respiratory tract infectionInfections and infestations | 7/61 | 14/135 |
| DizzinessNervous system disorders | 6/61 | 5/135 |
| ConstipationGastrointestinal disorders | 6/61 | 6/135 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/61 | 9/135 |
| Oedema peripheralGeneral disorders | 6/61 | 2/135 |
| Age, Continuous(years) | Placebo | Eltrombopag 50 mg QD | Total |
|---|---|---|---|
| Mean | 51.0 ± 14.72 | 46.5 ± 15.61 | 47.9 ± 15.45 |
| Sex: Female, Male(Participants) | Placebo | Eltrombopag 50 mg QD | Total |
|---|---|---|---|
| Female | 43 | 93 | 136 |
| Male | 19 | 42 | 61 |
| Race/Ethnicity, Customized(participants) | Placebo | Eltrombopag 50 mg QD | Total |
|---|---|---|---|
| African American/African | 1 | 2 | 3 |
| American Indian/Alaska native | 4 | 8 | 12 |
| East Asian | 10 | 19 | 29 |
| South-East Asian | 3 | 2 | 5 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 1 |
| White/Arabic/North African | 2 | 6 | 8 |
| White/Caucasian/European | 42 | 95 | 137 |
| Mixed Race | 0 | 2 | 2 |
| Stratification variable(Participants) | Placebo | Eltrombopag 50 mg QD | Total |
|---|---|---|---|
| Use of ITP medication at randomization | 31 | 63 | 94 |
| Splenectomy at randomization | 21 | 50 | 71 |
| Platelet count less or equal 15,000 per microliter | 30 | 67 | 97 |
Showing the first 100 of 115 sites across 25 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag
Purpura, Thrombocytopenic, Idiopathic →